CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS

Nicolás Fissolo, PhD, Clara Matute-Blanch, MSc, Mohamoud Osman, BSc, Carme Costa, PhD, Rucsanda Pinteac, MSc, Berta Miro, PhD, Alex Sanchez, PhD, Verónica Brito, PhD, Irena Dujmovic, MD, Margarete Voortman, MSc, Michael Khalil, PhD, Eva Borrás, PhD, Eduard Sabidó, PhD, Shohreh Issazadeh-Navikas, PhD, Xavier Montalban, MD, and Manuel Comabella Lopez, PhD

Objectives
To identify biomarkers associated with progressive phases of MS and with neuroprotective potential.

Methods
Combined analysis of the transcriptional and proteomic profiles obtained in CNS tissue during chronic progressive phases of experimental autoimmune encephalomyelitis (EAE) with the transcriptional profile obtained during the differentiation of murine neural stem cells into neurons. Candidate biomarkers were measured by ELISA in the CSF of 65 patients with MS (29 with relapsing-remitting MS [RRMS], 20 with secondary progressive MS, and 16 with primary progressive MS [PPMS]) and 30 noninflammatory neurologic controls (NINCs).

Results
Integrative analysis of gene and protein expression data identified 2 biomarkers, the serine protease inhibitor Serpina3n and the calcium-binding protein S100A4, which were upregulated in chronic progressive EAE and whose expression was induced during neuronal differentiation. Immunofluorescence studies revealed a primarily neuronal expression of S100A4 and Serpina3n during EAE. CSF levels of SERPINA3, the human ortholog of murine Serpina3n, and S100A4 were increased in patients with MS compared with NINCs (SERPINA3: 1,320 vs 838.6 ng/mL, p = 0.0001; S100A4: 1.6 vs 0.8 ng/mL, p = 0.02). Within the MS group, CSF SERPINA3 levels were significantly elevated in patients with progressive forms, mainly patients with PPMS compared with patients with RRMS (1,617 vs 1,129 ng/mL, p = 0.02) and NINCs (1,617 vs 838.6 ng/mL, p = 0.0001). Of interest, CSF SERPINA3 levels significantly correlated with CSF neurofilament light chain levels only in the PPMS group (r = 0.62, p = 0.01).

Conclusion
These results point to a role of SERPINA3 as a biomarker associated with the progressive forms of MS, particularly PPMS.
MS is a chronic inflammatory, demyelinating, and neurodegenerative disease of CNS and a leading cause of neurologic disability in young adults.1 The disease is characterized by an inflammatory component, which predominates in the initial relapsing-remitting phases, and a neurodegenerative component associated with the progressive stages of the disease, although it can be present early in the disease course.2 Over the last decades, the immunologic aspects of MS have been extensively investigated; however, the mechanisms leading to neurodegeneration and tissue repair are not yet well understood.

Whereas currently approved MS therapies are highly effective to suppress the predominantly inflammatory component observed in patients with relapsing-remitting MS (RRMS), these therapies remain largely ineffective in patients with progressive forms of the disease in whom the neurodegenerative component dominates.3,4 Similarly, available treatments have shown limited neuroprotective efficacy. In this context, a better understanding of the mechanisms underlying neurodegeneration and neuroregeneration in MS may set the rationale for the design of effective therapies to stop disease progression and/or enhance neuroprotection.

In the present study, we pursued to identify biomarkers of disease progression that may have neuroregenerative potential. To this end, in a first phase of the study, we searched for biomarkers that, on the one hand, were upregulated in CNS tissue during the chronic progressive phases of experimental autoimmune encephalomyelitis (EAE) and, on the other hand, were upregulated during the differentiation of neural stem cells (NSCs) to neurons. In a second phase of the study, selected biomarkers were measured in CSF of patients with MS with different clinical forms of the disease to confirm its potential as biomarkers of progression.

**Methods**

**Mice**

All experiments were performed in 5- to 8-week-old female C57BL6/J mice (Harlan, Lesmo, Italy) in strict accordance with European Union and governmental regulations (Generalitat de Catalunya Decret 214/97 July 30). The Ethics Committee on Animal Experimentation of the Vall d’Hebron Research Institute approved all procedures described in the study (protocol numbers: 70/13, 81/17 CEEA).

**EAE Induction**

Anesthetized C57BL/6 mice (n = 4/group) were immunized with subcutaneous injections of myelin oligodendrocyte glycoprotein (MOG)35-55 (50 μg) (Peptide Synthesis Facility, Universitat Pompeu Fabra, Barcelona, Spain) in phosphate buffered saline (PBS) emulsified in complete Freund adjuvant (Sigma Chemical, St Louis, MO) and supplemented with 2 mg/mL Mycobacterium tuberculosis H37RA (Difco Laboratories, Detroit, MI). Control animals (n = 4/group) received only PBS. All animals received an IV injection of 150 ng Pertussis toxin in 100 μL PBS on the day of immunization and another doses 48 hours later. Mice were weighted and examined daily for clinical signs of EAE, with the following scale: grade 0, no clinical disease; grade 1, tail weakness or tail paralysis; grade 2, hind leg paraparesis; grade 3, hind leg paralysis; grade 4, paraplegia with forelimb weakness or paralysis; and grade 5, moribund state or death.5

**Immunofluorescence histochemistry**

For immunofluorescence, we used the following antibodies at the dilution listed: goat polyclonal anti-Serpina3n antibody (1:5; purchased from R&D Systems, Minneapolis, MN, cat. No. AF4709); rabbit polyclonal anti-S100A4 antibody (1:10; purchased from Abcam, Cambridge, MA, cat. no. ab41532); antigliarial fibrillary acid protein (GFAP) Alexa Fluor-488 conjugated antibody (1:50; purchased from ebioScience, Vienna, Austria, cat. no. 53-9892-82); and chicken anti-β-Tubulin Isotype III polyclonal antibody (1:60; purchased from Abcam, cat.no. 117716). The following secondary antibodies were used: Alexa Fluor-568 rabbit anti-goat IgG (1:300; purchased from Invitrogen, Waltham, MA, cat. no. A11079); Alexa Fluor-594 goat anti-rabbit (1:300; purchased from Invitrogen, cat. no. A11012); and Alexa Fluor-488 goat anti-chicken (1:300; purchased from Invitrogen, cat. no. A11039). 4’,6-diamidino-2-fenilindol (DAPI)-Pacific blue (1:30,000; purchased from Invitrogen, cat. no. D3571) was used for nuclei visualization.

Immunofluorescence histochemistry (IFHC) was performed on CNS tissue obtained on d16 and d50 pi. The staining procedure started with deparaffinization and rehydration followed by heat-induced epitope retrieval step with 10 mM
sodium citrate buffer pH 6.0. For S100A4 sections, slides were blocked in normal 5% goat serum. For Serpina3n sections, slides were blocked in 0.3% Triton X-100 and 0.24 g glycine. Slides were incubated overnight with primary antibodies (diluted in buffer containing 1% bovine serum albumin (BSA) and 0.3% Triton X-100) at 4°C. Slides were afterward washed 3 times in 1XPBS-T for 5 minutes and incubated with secondary antibodies for 1 hour. Slides were then washed 3 times in 1XPBS-T for 3 minutes, and DAPI was added to the specimens for 10 minutes. After washing 3 times in 1XPBS-T for 1 minute, slides were mounted with ProLong Gold antifade (Invitrogen) and air dried. Images were taken with ZEN-2011 software on Zeiss microscope (AXIO M2; Göttingen, Germany) with Zeiss (AxioCam) camera connected. Images were processed with Adobe Photoshop and Adobe Illustrator (Adobe Systems, San Jose, CA).

**Generation of Mouse NSCs and Differentiation Into Neurons**

NSCs were isolated from forebrain C57BL/6 mice (n = 4) E16-18. Briefly, the forebrain was dissected, cut into small fragments (<1 mm³), and digested with papain. The digested tissue fragments were washed through fire-polished fine tip Pasteur pipet to obtain a single cell suspension and cultured in DMEM/F12 medium (Invitrogen) containing B27 supplement, 20 ng/mL fibroblast growth factor basic (bFGF) (Invitrogen), 20 ng/mL epidermal growth factor (EGF) (Invitrogen), in the presence of FBS 5% and retinoic acid (0.05 μM). Neurons were characterized by immunofluorescence staining with MAP2 (microtubule-associated protein 2) and doublecortin (DCX).

**Gene Expression Microarrays**

Total messenger RNA (mRNA) and proteins (frozen at −80°C until used) from the brain and spinal cord were extracted using TRI reagent (Sigma Chemical) following the manufacturer’s instructions. A similar protocol was followed to obtain total RNA from neurons and NSCs. Gene expression from mice tissue, NSCs, and neurons was evaluated with the Affymetrix Mouse Gene 1.0 Array using the Ambion WT Expression kit for target amplification (Applied Biosystems, Foster City, CA) and the target labeling with the WT Terminal Labeling kit (Affymetrix, Santa Clara, CA). The Affymetrix Expression Console software was used for gene-level log-scaled robust multiarray analysis. The linear models for microarray data (LIMMA) R package was used to identify differentially expressed genes between mice with EAE and control groups (PBS) and between NSCs and neurons. Differentially expressed genes in the 2-sample t-test with p value <0.05 were considered significant.

**Determination of Serpina3n and S100A4 Expression Levels in CNS by qPCR**

mRNA expression levels for Serpina3n and S100A4 were determined in CNS samples from 4 EAE and 4 control animals at days 8, 16, 36, 50, and 90 pi. Total RNA was taken from the same samples that had been used for the microarrays, and complementary DNA (cDNA) synthesized using the High capacity cDNA Archive kit (Applied Biosystems). Serpina3n and S100A4 transcripts were determined with TaqMan gene expression assays (Mm00776439_m1 and Mm00803372_g, respectively; Applied Biosystems). Obtained values were normalized according to the level of expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase. Assays were run on the ABI PRISM® 7900HT system (Applied Biosystems), and data were analyzed with the 2-ΔΔCT method. Results were expressed as fold change in gene expression in EAE mice compared with controls (calibrators).

**Mass Spectrometry Sample Preparation**

Samples (10 μg) were reduced with dithiothreitol (30 nmol, 37°C, 60 minutes) and alkylated with iodoacetamide (60 nmol, 25°C, 30 minutes) in the dark. The resulting protein extract was diluted in 2 M urea with 200 mM ammonium bicarbonate for digestion with endoproteinase LysC (1:10 w:w, 37°C, o/n, Wako, Osaka, Japan), and afterward diluted 2-fold with 200 mM ammonium bicarbonate for trypsin digestion (1:10 w:w, 37°C, 8 hours, Promega, Madison, WI). After digestion, peptide mix was acidified with formic acid and desalted with a MicroSpin C18 column (The Nest Group, Inc., Southborough, MA) before Liquid chromatography (LC)-MS/MS analysis.

**Chromatographic and Mass Spectrometric Analysis**

Samples were analyzed using a LTQ-Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled to an EASY-nLC 1000 (Proxeon; Thermo Fisher Scientific, Denmark). Peptides were loaded directly onto the analytical column to be separated by reversed-phase chromatography by a 25-cm column with a 75 μm of inner diameter, packed with 1.9 μm C18 particles (Nikkyo Technos, Tokyo, Japan). Chromatographic gradients started at 97% buffer A (0.1% formic acid in water) and 3% buffer B (0.1% formic acid in acetonitrile) with a flow rate of 250 nL/minute for 5 minutes and gradually increased to 35% buffer B and 65% A in 120 minutes.

The mass spectrometer was operated in positive ionization mode with nanospray voltage set at 2 kV and source temperature at 275°C. Ultramark 1621 was used for external calibration of the FT mass analyzer prior the analyses, and an internal calibration was performed using the background polysiloxane ion signal at m/z 445.1200. The acquisition was performed in data-dependent acquisition mode, and full MS scans with 1 micro scans at resolution of 120,000 were used over a mass range of m/z 400–1,500 with detection in the Orbitrap mass analyzer. In each cycle of data-dependent acquisition analysis, following each survey scan, the most intense ions above a threshold ion count of 5,000 were selected for fragmentation. The number of selected precursor ions for fragmentation was determined by the Top Speed acquisition algorithm and a dynamic exclusion of 60 seconds. Fragment
Mass Spectrometry Data Analysis
Acquired spectra were analyzed using the Proteome Discoverer software suite (v1.4; Thermo Fisher Scientific) and the Mascot search engine v2.5, Matrix Science. The data were searched against a Swiss-Prot mouse database (as of April 2015) plus a list of common contaminants and all the corresponding decoy entries. For peptide identification, a precursor ion mass tolerance of 7 ppm was used for MS1 level, trypsin was chosen as enzyme, and up to 3 missed cleavages were allowed. The fragment ion mass tolerance was set to 0.5 Da for MS2 spectra. False discovery rate (FDR) for identification of peptides was set to a maximum of 1%.

Peptide quantification data were retrieved from the extracted ion chromatograms, and the obtained data used to perform protein relative quantitation using the R package MStats v2.6. Protein abundance changes were considered significant when adjusted p value was below 0.05.

The raw proteomics data have been deposited to the PRIDE repository with the data set identifier PXD018173.

Integrative Analysis of Gene and Protein Expression Data
Data sets of gene expression from transcriptome and protein relative abundances from proteome analyses were obtained. The most differentially expressed genes and proteins between the EAE and control groups (adjusted p value of 0.05) were selected on both data sets separately by a cutoff according to SD. Afterward, the top genes and proteins were matched in a common list and used for the integrative analysis. Finally, biomarkers of disease progression were identified by 2 complementary approaches. First, the Partial Least Squares (sPLS) canonical method using the “mixOmics” R package was used to integrate both data sets for each time point, applying a cutoff threshold of 0.85 to restrict the analysis to stronger gene-protein associations. Second, each data set was analyzed along time with a 2-way backward regression with a 5% FDR with the maSigPro R package. sPLS looked at the correlation between genes and proteins at each given time point, and the time-course analysis focused at the relationship along each time point on a gene-by-gene and a protein-by-protein basis.

Patients
A cohort of 65 untreated patients with MS and 30 non-inflammatory neurologic controls (NINCs) was included in the study. The MS group comprised 29 patients with RRMS, 20 with secondary progressive MS (SPMS), and 16 with primary progressive MS (PPMS). Diagnosis was based on 2005 and 2010 revised McDonald criteria. For patients with SPMS, progression was defined as a confirmed increase at 6 months in the Expanded Disability Status Scale (EDSS) of 1 point for EDSS < 5.5 and 0.5 points for EDSS ≥ 5.5. Table 1 summarizes demographic and clinical characteristics of patients with MS and controls included in the study.

Quantification of SERPIN A3 and S100A4 Levels in CSF From Patients With MS and Controls by ELISA
CSF samples were collected by lumbar puncture and centrifuged for 5 minutes at 1,500 rpm to remove cells. Samples were aliquoted and frozen at –80°C until used. CSF levels of SERPIN A3 (the human ortholog of murine Serpina3n, also known as a1-antichymotrypsin) were measured with the human alpha-1-antichymotrypsin ELISA kit (Abnova, Taipei, Taiwan) following 1:40 dilution, and levels of S100A4 were determined with the human S100A4 ELISA kit (CycLex Co., Nagoya, Japan). All samples were measured in duplicate following the specific protocols provided by the manufacturers. The intra- and interassay coefficients of variation for SERPIN A3 were 2.5% and 10.4%, respectively, and for S100A4 5.0% and 17.0%, respectively.

Quantification of CSF Neurofilament Light Chain Levels by Single Molecule Array (Simoa)
In patients with RRMS (n = 29) and PPMS (n = 16), CSF levels of neurofilament light chain (NFL) were measured using commercially available NFL immunoassay kits (Quanterix, Billerica, MA, cat#103186) run on the fully automated ultrasensitive Simoa HD-1 Analyzer (Quanterix). Samples were run in duplicate in accordance with manufacturers’ instructions with appropriate standards and internal controls. The intra-assay and interassay coefficients of variation were 5% and 9%, respectively.

Statistical Analysis
Statistical analysis was conducted with the SPSS 17.0 package (SPSS Inc., Chicago, IL) for MS Windows. The significance of differences among experimental groups for microarrays, mass spectrometry, and quantitative PCR (qPCR) was assessed by the 2-tailed Student t test or Mann-Whitney U test. One-way analysis of variance followed by the Tukey post hoc test was applied for mean protein levels comparisons among groups. Partial correlations adjusting
Integrative Omics Analysis Reveals Upregulation of Serpina3n and S100A4 During Chronic Progressive EAE and Neurogenesis

Two multivariate approaches (sPLS and 2-way backward regression) were used to integrate genomics and proteomics data sets to assess what molecules identified at both the expression and translational levels could better explain the chronic progressive phase of EAE in comparison to controls and use these candidates as potential biomarkers. Although sPLS looked at the correlation on a gene-by-protein basis at each given time point separately, the time-course analysis focused at the relationship along each time point on a gene-by-gene and a protein-by-protein basis. As shown in figure 1D, the sPLS analysis identified a total of 380 genes and proteins showing similarly upregulated expression at each time point of the study. Time-course analysis by 2-way backward regression identified 227 genes and proteins showing a similar pattern of expression. Intersection between the 3 sets of results (i.e., sPLS analysis, time-course analysis, and neuronal differentiation) revealed 2 molecules, Serpina3n and S100A4, that showed a high expression in the progressive phases of EAE and were upregulated during neurogenesis (figure 1D). Tables 2 and e-1 (links.lww.com/NXI/A366) show the list of candidate molecules scoring 2 or 3 in the different approaches used for analysis.

Clinical disease score after EAE induction is represented in figure 2A. Figure 2B shows the time-course gene and protein expression for Serpina3n and S100A4 in CNS tissue. Gene expression levels and protein abundance of Serpina3n and S100A4 were significantly increased in the chronic progressive phases of EAE compared with the reference time point (d8) and with control mice (figure 2B). We also performed qPCR for Serpina3n and S100A4 to validate microarray findings. qPCR also included an additional time point at d16 to discriminate between acute and chronic EAE phases.
As shown in figure 2C, mRNA expression levels of Serpina3n measured by qPCR over time faithfully mirrored those obtained with gene expression microarrays, with higher levels in chronic EAE. Although a similar gene expression pattern was also observed for S100A4 over time, mRNA expression levels were more pronounced at d16 and d36 compared with later chronic time points, suggesting that S100A4 expression is strongly induced by inflammation (figure 2C). Finally, as shown in figure 2D, gene expression levels for Serpina3n and S100A4 were significantly upregulated in neurons compared with NSCs.

**Histology Studies Reveal a Primarily Neuronal Expression of Serpina3n and S100A4 During EAE**

Cellular expression of Serpina3n and S100A4 was determined with double IFHC in EAE during the course of the disease. CNS tissue from both acute inflammatory (d16) and chronic progressive (d50) time points was included for comparison purposes. Mouse cerebellum, hippocampus, and spinal cord slides were stained with antibodies against Serpina3n or S100A4, β-III-Tubulin and GFAP were used as neuronal and astrocytic markers, respectively. Both at d16 and d50, Serpina3n colocalized with β-III-Tubulin in cerebellar Purkinje cells.
cells and neurons of the granular layer (figure 3A), hippocampal pyramidal neurons of the CA1 region (figure 3B), and spinal cord neurons (figure e-1A, links.lww.com/NXI/A365) of CNS tissue from EAE mice but not from PBS-immunized mice. Of interest, for all tissue sections, neuronal expression of Serpina3n was more evident in the chronic time point compared with the acute time point, findings that are in agreement with the qPCR data suggesting that Serpina3n expression is not significantly induced during the inflammatory insult (figure 3, A and B, figure e-1A). No colocalization was observed in CNS sections of EAE or control mice stained for Serpina3n and GFAP (figure 3, C and D).

<table>
<thead>
<tr>
<th>Entrez ID</th>
<th>Symbol</th>
<th>Description</th>
<th>NSCs vs neurons</th>
<th>sPLS network</th>
<th>Time course</th>
<th>Sum</th>
</tr>
</thead>
<tbody>
<tr>
<td>20716</td>
<td>Serpina3n</td>
<td>Serine (or cysteine) peptidase inhibitor, clade A, member 3N</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>20198</td>
<td>S100a4</td>
<td>S100 calcium-binding protein A4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>11430</td>
<td>Acox1</td>
<td>Acyl-Coenzyme A oxidase 1, palmitoyl</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>13030</td>
<td>Ctsb</td>
<td>Cathepsin B</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>66259</td>
<td>Camk2n1</td>
<td>Calcium/calmodulin-dependent protein kinase II inhibitor 1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>69786</td>
<td>Tprkb</td>
<td>Tp53rk-binding protein</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>14469</td>
<td>Gbp2</td>
<td>Guanylate-binding protein 2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>19682</td>
<td>Rdh5</td>
<td>Retinol dehydrogenase 5</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>11816</td>
<td>ApoE</td>
<td>Apolipoprotein E</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>20615</td>
<td>Snapin</td>
<td>SNAP-associated protein</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>27883</td>
<td>Tango 2</td>
<td>Transport and golgi organization 2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>56188</td>
<td>fxyd1</td>
<td>FXYD domain-containing ion transport regulator 1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>11303</td>
<td>Abca1</td>
<td>ATP-binding cassette, subfamily A (ABC1), member 1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>12266</td>
<td>C3</td>
<td>Complement component 3</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>12268</td>
<td>C4b</td>
<td>Complement component 4B</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>12527</td>
<td>CD9</td>
<td>CD9 antigen</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>13010</td>
<td>Cst3</td>
<td>Cystatin C</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>16854</td>
<td>Lgals3</td>
<td>Lectin, galactose binding, soluble 3</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>17035</td>
<td>Lxn</td>
<td>Latexin</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>17096</td>
<td>Lyn</td>
<td>LYN proto-oncogene, Src family tyrosine kinase</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>18301</td>
<td>Fxyd5</td>
<td>FXYD domain-containing ion transport regulator 5</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>20148</td>
<td>Dhrs3</td>
<td>Dehydrogenase/reductase (SDR family) member 3</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>21356</td>
<td>Tappb</td>
<td>TAP-binding protein</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>26362</td>
<td>Axl</td>
<td>AXL receptor tyrosine kinase</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>74011</td>
<td>Slc25a27</td>
<td>Solute carrier family 25, member 27</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>74559</td>
<td>elo17</td>
<td>ELOVL family member 7, elongation of long chain fatty acids (yeast)</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>214944</td>
<td>Mob3b</td>
<td>MOB kinase activator 3B</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>243906</td>
<td>Zfp14</td>
<td>Zinc finger protein 14</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>321007</td>
<td>Serac1</td>
<td>Serine active site containing 1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

Abbreviation: NSC = neural stem cell.

Overlapping molecules between the 3 bioinformatics approaches used for analysis. Only molecules upregulated during the differentiation of NSCs to neurons with a p value < 0.001 are shown. Entrez ID = identifier for a gene per the NCBI Entrez database (http://www.ncbi.nlm.nih.gov/gene).
Figure 2 Serpina3n and S100A4 Levels Are Significantly Upregulated in Chronic EAE and During Neurogenesis

(A) Disease course after EAE induction. Only time points chosen for analyses are annotated. (B) Gene expression levels and protein abundance for Serpina3n and S100A4 were determined by means of microarrays and mass spectrometry, respectively, in CNS samples obtained at d8, d36, d50, and d90 postimmunization (n = 4). (C) messenger RNA expression levels for Serpina3n and S100A4 determined by quantitative PCR in CNS from EAE mice or control mice during disease course. Gray bars indicate the additional time point during the inflammatory phase of the disease (d16 postimmunization). Glyceraldehyde-3-phosphate dehydrogenase was used as endogenous control. Results are expressed as fold change in gene expression in EAE mice relative to control mice (calibrators). (D) Gene expression levels for Serpina3n and S100A4 determined by means of microarrays in neural stem cells and differentiated neurons. For (A–D), depicted values represent the mean ± standard error of the mean. *** p < 0.001, ** p < 0.01, * p < 0.05. EAE = experimental autoimmune encephalomyelitis; NSC = neural stem cell.
Figure 3 Serpina3n Expression Is Restricted to Neurons During EAE

A

Cerebellum

PBS d16

EAE d16

PBS d50

EAE d50

B

Hippocampus

PBS d16

EAE d16

PBS d50

EAE d50

C

PBS

EAE

PBS

EAE

D

PBS

EAE

PBS

EAE

Representative images of Serpina3n expression in neurons (A–B) and astrocytes (C–D) of PBS (controls) or EAE mice at d16 and d50 postimmunization. Tissues were stained for Serpina3n (red), β-III-Tubulin (neuronal marker, green), and DAPI (blue) (A–B). Colocalization of Serpina3n in astrocytes was evaluated by staining for Serpina3n (red), GFAP (astrocyte marker, green), and DAPI (blue) (C–D). EAE = experimental autoimmune encephalomyelitis; GFAP = glial fibrillary acid protein.

Serpina3n expression is restricted to neurons during EAE course.

Similar to the pattern observed for Serpina3n, cerebellum slides showed colocalization of S100A4 and β-III-Tubulin in Purkinje cells, as well as neurons from the granular region of EAE animals, whereas no expression was observed in control mice (figure 4A). At d50 pi, S100A4 expression was not only observed in Purkinje cells but also in neurons from the molecular region of the cerebellum of EAE mice compared with the PBS group (figure 4A). Hippocampal CA1 pyramidal neurons clearly showed S100A4 expression in EAE (figure 4B). By contrast, no S100A4 expression was found in neurons from the spinal cord neither in EAE nor in PBS (figure e-1C, links.lww.com/NXI/A365). Double staining for S100A4 and GFAP revealed no major expression of S100A4 in astrocytes in any of the CNS analyzed regions, although occasional double-positive cells were detected in the hippocampus (figure 4, C and D, figure e-1D).

SERPINA3 Levels Are Increased in CSF From Patients With Progressive forms of MS

To investigate whether selected biomarkers of progression with neuroregenerative potential identified in EAE could also play a role in MS, levels of SERPINA3 and S100A4 were measured in CSF samples from a cohort of patients with MS and neurologic controls. As shown in figure 5A, CSF SERPINA3 and S100A4 levels were significantly increased in the whole group of patients with MS compared with NINCs. Stratification of patients with MS into different clinical forms revealed that the highest CSF SERPINA3 levels were observed in patients with progressive MS, particularly in patients with PPMS, and differences were statistically significant for patients with SPMS and PPMS compared with NINCs, and...
also for patients with PPMS compared with patients with RRMS. In contrast, although CSF S100A4 levels were slightly increased in patients with RRMS, no statistically significant differences were observed across MS groups and NINCs (figure 5B). CSF levels of SERPINA3 and S100A4 did not correlate with EDSS scores at the time of sample collection or the number of gadolinium-enhancing lesions in brain MRI scans performed in proximity to lumbar puncture (data not shown). Similarly, segregation of SERPINA3 and S100A4 CSF levels into high and low according to a cutoff value based on median protein levels did not reveal significant differences between patients with MS with high and low SERPINA3 and S100A4 CSF levels and EDSS scores or the number of contrast-enhancing lesions (data not shown).

**CSF SERPINA3 Levels Correlate With CSF NFL Levels in Patients With PPMS**

To investigate whether SERPINA3 and S100A4 are biomarkers associated with disease progression or instead may have neuroprotective roles in MS, we measured CSF levels of NFL in patients with RRMS and PPMS. As shown in figure 6A, CSF levels of NFL and SERPINA3 significantly correlated in the whole group of patients ($r = 0.56, p = 0.001$). Of interest, association was driven by the PPMS group insomuch as statistical significance remained significant only in patients with PPMS following segregation into clinical forms ($r = 0.62, p = 0.01$; figure 6A). In contrast, CSF NFL levels did not correlate with CSF S100A4 levels neither in the whole group of patients nor after segregation into RRMS and PPMS clinical forms (figure 6B). These findings point to SERPINA3 as a biomarker associated with disease progression in patients with PPMS.

**Discussion**

In the present study, we aimed to identify molecules associated with disease progression that may have
neuroregenerative capacity. To this end, we used gene expression microarrays combined with mass spectrometry analysis to determine which genes and proteins were significantly modulated using a chronic progressive EAE model. Statistical analysis of transcriptional and proteomic data sets from different phases of the disease identified a series of molecules that were upregulated in the chronic progressive phases of EAE. In parallel, these molecules were matched with genes upregulated during the differentiation process from NSCs to neurons. Our results showed a selective increase in gene and protein expression of Serpina3n and S100A4 in the progressive phases of EAE and upregulation of both markers during the differentiation of NSCs to neurons. Serpina3n and S100A4 showed a primarily expression in neurons that, particularly for Serpina3n, was increased in the chronic progressive stages of the disease. These observations in the EAE mouse model were further substantiated for Serpina3n in CSF samples of patients with MS, where SERPINA3 levels, the human ortholog of murine Serpina3n, were increased in patients with the progressive forms of MS (SPMS and PPMS) compared with patients with RRMS and NINCs, postulating Serpina3n/SERPINA3 as a biomarker of disease progression with potential for neuroregeneration.

Gene and protein expression profiling during the course of EAE offers a powerful approach for understanding the molecular changes that characterize the disease, which in turn provide a starting point to identify new molecules involved in the disease. Previous reports applied either transcriptional or proteomic profiling analyses to identify new biomarkers and therapeutic candidates in the context of MS.16–18 In those analyses, each feature from each technology (transcripts and proteins) was analyzed independently through univariate statistical methods; however, such analyses ignored relationships between the different features and may have missed crucial biological information. Indeed, biological features act together to control biological systems and signaling pathways. Multivariate approaches, which model features as a set, can offer a more insightful picture of a biological system and complement results obtained from univariate methods. In this regard, omics integration analyses have been developed to analyze large amounts of biological data to identify molecular signatures across multiple data sets.19

We performed differentially expressed analysis by means of gene expression microarrays and mass spectrometry at different stages of EAE and identified 1,763 common molecules.

As described in Methods, CSF levels of SERPINA3 and S100A4 were determined by ELISA and represented as ng/mL in the whole MS group and NINCs (A) and in patients with MS classified according to the different clinical forms of MS (B). For the sake of clarity, only significant p values are shown in the graphs. Number of individuals included in the study is shown in parentheses. One-way analysis of variance followed by multiple comparisons test was performed comparing all groups. ***p < 0.001, **p < 0.01, *p < 0.05. NINC = noninflammatory neurologic control; PPMS = primary progressive MS; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS.

Figure 5 Dot Plots Showing Levels of SERPINA3 and S100A4 in CSF Samples of Patients With MS and Controls
To select the molecules showing the highest differences with respect to the entire data set, only 441 genes and 227 proteins were chosen for further bioinformatic analysis that allowed us to focus only on those molecules whose expression was highly modified as the cause of the disease. As we were particularly interested in markers associated with the progressive phase of EAE, we chose 2 bioinformatic analyses, sPLS that investigates gene-protein associations, and a time-course study using a 2-way backward regression to select molecules displaying a pattern of low expression at the initial stages and a clear increase in the progressive phases of the disease. We identified 47 molecules, at the gene and protein level, that met these parameters. Based on these observations, it was reasonable to think that in addition to biomarkers of disease progression, those molecules could also be involved in neurodegeneration. Nevertheless, the mere increase of the levels of certain molecules in the CNS does not prove their pathogenicity in EAE progression, as previously illustrated in different EAE models, in which transcriptional studies identified molecules whose expression was increased in late phases of EAE, such as anti-inflammatory cytokines, growth factors, and oligodendroglial progenitor and neuroglial regeneration markers.16,20

In parallel to our findings on biomarkers upregulated during the chronic progressive phases of EAE, we aimed to explore whether these molecules were also upregulated during neuronal differentiation. To this end, microarray analysis was performed in NSCs differentiated into neurons, resulting in a total of 1,705 genes upregulated in neurons compared to NSCs. Then, we examined the overlapping of identified biomarkers of disease progression, together with molecules upregulated during neuronal differentiation. As a result, we observed that 2 markers, Serpina3n and S100A4, matched with the biomarkers of disease progression previously identified in the EAE model. According to several publications, new functional neurons are constantly generated from NSCs throughout life,21 and stem cells with potential to give rise to new neurons reside in many different regions of the mammalian brain.22,23 Hence, neurogenesis occurs and persists in the adult brain, where it may contribute to repair and recovery after injury.

Gene expression profiles determined by microarrays revealed that Serpina3n and S100A4 levels are low at early EAE (d8 pi), similar to the control group, but then their expression was
highly increased during disease progression. Likewise, at the protein level, almost no expression for both markers was detected in the inflammatory phase of the disease, indicating that both markers are associated with the progressive phases of EAE. To validate microarray data and to determine whether levels of both markers were induced by inflammation, gene expression experiments by means of qPCR included an additional time point (d16 pi). At the inflammatory phase of the disease (d16 pi), S100A4 levels were significantly increased and remained high at later time points, suggesting that S100A4 could also be a biomarker strongly induced by inflammation. In contrast, expression levels for Serpina3n were increasingly elevated during EAE course and peaked at chronic time points (from d36 onward), findings that point to Serpina3n as a biomarker of disease progression that is not significantly influenced by the inflammatory process. In the context of EAE, no publications have determined the expression levels of Serpina3n during the disease. Conversely, a proteomic approach identified S100A4 among other 3 proteins whose levels were increased during EAE course of relapse-remitting and chronic models of the disease.24

Serpina3n is a secreted peptidase inhibitor of the serpin family,25 whose expression is induced by inflammation and nerve injury.26,27 S100A4 is a Ca-binding protein, member of the S100 family of proteins, which plays an important role in tumor progression,28 but is also overexpressed in the damaged human and rodent brain.29 We examined the expression of both markers by immunofluorescence staining in cerebellum, hippocampus, and spinal cord tissues of EAE mice. Our findings showed a strong colocalization of Serpina3n with β-III-Tubulin+ neurons in EAE at d16, but not in control mice. In addition, levels of Serpina3n in neurons were increased at d50 pi, showing a correlation with the chronic progressive phases of the disease. On the other hand, no double staining Serpina3n/GFAP was observed neither at d16 nor at d50 pi in EAE and PBS-immunized mice, indicating that Serpina3n is not detected in astrocytes during the EAE course. β-III-Tubulin+ neurons were coimmunostained for S100A4 in EAE but not in control animals, whereas no differences were observed between d16 and d50 pi. GFAP+ astrocytes showed sporadic expression of S100A4 in the hippocampus. Immunostaining of CNS tissues correlated with gene expression levels observed during EAE, suggesting that S100A4 is strongly induced by inflammation, and Serpina3n is a marker associated with the progressive phases of the disease.

It is important to mention that previous reports have described both Serpina3n and S100A4 as secreted markers of reactive astrocytes30,31 that, after brain injury, have been detected in human and mouse neurons.32–34 In this context, our present observations suggest that Serpina3n and S100A4 may be produced by reactive astrocytes at early EAE, and later, both markers are secreted to neurons where they may participate in repairing mechanisms. In this regard, a previous work by Haile et al.35 demonstrated that in vivo treatment with Serpina3n attenuated EAE severity through inhibition of the enzymatic activity of the granzyme B released by activated T cells, which protected from neuronal death. Similarly, in models of brain injury, increased levels of S100A4, either released by reactive astrocytes or after treatment with recombinant S100A4, induced neuroprotection by rescuing neurons from death and stimulating neuronal differentiation.29,36

In the present study, we found that patients with MS showed increased CSF levels of SERPINA3 and S100A4 compared with neurologic controls. Within the MS group, differences were only observed for SERPINA3 in the progressive forms of the disease, SPMS and PPMS, compared with controls and RRMS. Other studies have also demonstrated elevated levels in CSF samples from patients with MS compared with controls.37,38 However, in those studies, no comparisons were performed between the different clinical forms. In other pathologic conditions, SERPINA3 was found to be increased in the CSF of patients with Alzheimer disease,39,40 and levels correlated with the degree of disease severity. In this context, SERPINA3 has been associated with hyperphosphorylation and tau aggregation leading to neurodegeneration.41 These results most likely reflect the different roles that Serpina3n/SERPINA3 may be playing depending on the nature of the CNS insult42 and certainly underscore the need of future studies to gain more insight into the complex and diverse Serpina3n/SERPINA3 functions. However, the finding of a significant correlation between CSF SERPINA3 levels and CSF NFL levels in patients with PPMS suggests that SERPINA3 is a biomarker associated with disease progression rather than neuroprotection.

Because of the abundance of SERPINA3 in blood, a limitation of the study is the lack of SERPINA3 determinations in serum of patients to rule out a peripheral origin of the increased CSF SERPINA3 levels observed in patients with progressive MS. Although future studies are needed in this direction, the fact that blood-brain barrier permeability is decreased in patients with progressive MS43 makes this possibility unlikely.

In conclusion, we propose Serpina3n/SERPINA3 as a biomarker associated with the progressive forms of MS, particularly PPMS. Additional studies in large cohorts of patients with relapsing and progressive MS are needed to confirm SERPINA3 association with disease progression in patients with PPMS.

Acknowledgment
The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is a member of the ProteoRed PRB3 consortium, which is supported by grant PT17/0019 of the PE I+D+i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. The authors acknowledge support from the Spanish Ministry of Science, Innovation and Universities, “Centro de

Study Funding
This work was supported by grants from the Fondo de Investigación Sanitaria (FIS; grant number PI17/00596), Ministry of Science and Innovation, Spain; Generalitat de Catalunya Suport Grups de Recerca (2017 SGR 0527); and the Red Española de Esclerosis Múltiple (RD16/0015/0004) funded by the FIS.

Disclosure
The authors report no disclosures relevant to the manuscript.

Disclosure funded by the FIS. Ministry of Science and Innovation, Spain; Generalitat de Investigació Sanitaria (FIS; grant number PI17/00596), This work was supported by grants from the Fondo de Investigación Sanitaria (FIS; PI17/00596), Ministry of Science and Innovation, Spain; Generalitat de Catalunya Suport Grups de Recerca (2017 SGR 0527); and the Red Española de Esclerosis Múltiple (RD16/0015/0004) funded by the FIS.

Publication History

Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicolás Fissolo, PhD</td>
<td>Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca, Hospital Vall d’Hebron, Barcelona, Spain</td>
<td>Designed and conceptualized the study; analyzed the data; and drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Clara Matute-Blanch, MSc</td>
<td>Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca, Hospital Vall d’Hebron, Barcelona, Spain</td>
<td>Acquisition and analysis of the data</td>
</tr>
<tr>
<td>Mohamoud Osman, BSc</td>
<td>Biotech Research and Innovation Centre, University of Copenhagen, Denmark</td>
<td>Acquisition and analysis of the data</td>
</tr>
<tr>
<td>Carme Costa, PhD</td>
<td>Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca, Hospital Vall d’Hebron, Barcelona, Spain</td>
<td>Acquisition and analysis of the data</td>
</tr>
<tr>
<td>Rucsanda Pinteac, MSc</td>
<td>Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca, Hospital Vall d’Hebron, Barcelona, Spain</td>
<td>Acquisition and analysis of the data</td>
</tr>
<tr>
<td>Berta Miró, PhD</td>
<td>Statistics and Bioinformatics Unit, Institut de Recerca, Hospital Vall d’Hebron, Barcelona, Spain</td>
<td>Acquisition and analysis of the data</td>
</tr>
<tr>
<td>Alex Sanchez, PhD</td>
<td>Statistics and Bioinformatics Unit, Institut de Recerca, Hospital Vall d’Hebron, Barcelona, Spain</td>
<td>Acquisition and analysis of the data</td>
</tr>
<tr>
<td>Verónica Brito, PhD</td>
<td>Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca, Hospital Vall d’Hebron, Barcelona, Spain</td>
<td>Acquisition and analysis of the data</td>
</tr>
</tbody>
</table>

References


CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS
Nicolás Fissolo, Clara Matute-Blanch, Mohamoud Osman, et al.
*Neurol Neuroimmunol Neuroinflamm* 2021;8;
DOI 10.1212/NXI.0000000000000941

This information is current as of January 12, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/8/2/e941.full.html

References
This article cites 41 articles, 2 of which you can access for free at:
http://nn.neurology.org/content/8/2/e941.full.html#ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
http://nn.neurology.org/content/8/2/e941.full.html#otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Multiple sclerosis
http://nn.neurology.org/cgi/collection/multiple_sclerosis

Errata
An erratum has been published regarding this article. Please see next page or:
/content/8/3/e983.full.pdf

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus
In the article "CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS" by N. Fissolo et al.,1 Dr. Nicolás Fissolo should be listed as a corresponding author in addition to Dr. Manuel Comabella Lopez. Dr. Fissolo can be reached at nicolas.fissolo@vhir.org. The authors and editorial staff regret the omission.

Reference